StemCell Therapy

Targeted Nanoparticle Probes for Embryonic Stem Cell Derived Progenitor Cells
David Larocca. Advanced Cell Technology Inc., Burnham Institute for Medical Research, La Jolla, CA Pluripotent stem cells whether from embryonic (ES) or induced (iPS) cells offer a potentially unlimited source of replacement cells for treating human degenerative diseases associated with aging such as cardiovascular disease, macular degeneration, aging skin, diabetes, Parkinson #39;s, and Alzheimer #39;s disease. The availability of iPS cells will no doubt increase the number of research grade ES-like cell lines dramatically and may ultimately fulfill the need for patient specific stem cells. However, a significant problem and potential bottleneck to developing stem cell therapies is the development of efficient tools and technologies for directed differentiation of pluripotent stem cells toward therapeutic cell types. Currently, this process is poorly understood and often yields differentiated cells that represent only a few percent of the starting ES cells which are difficult to scale up. Identification of surface markers of lineage specific progenitor cells would provide tools for tracking, isolating and scaling these cells to improve differentiation yields and increase our understanding of ES cell differentiation in vitro. Toward this end, we have isolated progenitor cell-targeting peptides by selecting phage display libraries on differentiating ES cells. We have used the cell-targeting peptides or peptide phage themselves to target fluorescent nanoparticles (quantum dots) to ...From:Jeriaska JeriaskaViews:0 0ratingsTime:17:08More inEducation

More here:
Targeted Nanoparticle Probes for Embryonic Stem Cell Derived Progenitor Cells - Video

This entry was posted on November 17, 2012 at 10:43 am and is filed under Diabetes. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |